GeistHaus
log in · sign up

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer - Nature

doi.org

In a phase 1 trial, patients with pancreatic ductal adenocarcinoma who were treated with surgery and bespoke neoantigen mRNA vaccines combined with anti-PD-L1 and chemotherapy exhibited marked long-lived persistence of neoantigen-specific CD8+ T cell clones, which correlated with prolonged recurrence-free survival at a 3.2-year follow-up.

1 page links to this URL
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results - Nature Medicine
Nature Publishing Group US Zev A Wainberg; Colin D Weekes; Muhammad Furqan; Pashtoon M Kasi; Craig E Devoe; Alexis D Leal; Vincent Chung; James R Perry; Thian Kheoh; Lisa K McNeil; Esther Welkowsky; Peter C DeMuth; Christopher M Haqq; Shubham Pant; Eileen M O’Reilly

In the final analysis of a phase 1 trial evaluating a lymph node-targeting mutant KRAS peptide vaccine combined with CpG in the adjuvant setting for patients with KRAS mutant pancreatic or colorectal cancer, median relapse-free survival and overall survival were not reached for patients with robust antigen-specific T cell responses, and these responses were durable with evidence of antigen spreading.

6 inbound links article en Cancer immunotherapyColon cancerPancreatic cancer Cancer immunotherapyColon cancerPancreatic cancerBiomedicinegeneralCancer ResearchMetabolic DiseasesInfectious DiseasesMolecular MedicineNeurosciences CC BY 4.0